189 related articles for article (PubMed ID: 9209451)
1. Monitoring the efficiency of interferon-alpha therapy in chronic myelogenous leukemia (CML) patients by competitive polymerase chain reaction.
Hochhaus A; Lin F; Reiter A; Skladny H; Hehlmann R; Goldman JM; Cross NC
Leukemia; 1997 Apr; 11 Suppl 3():541-4. PubMed ID: 9209451
[TBL] [Abstract][Full Text] [Related]
2. Quantitative molecular methods to monitor the response of CML patients to interferon-alpha.
Hochhaus A; Lin F; Reiter A; Skladny H; Hehlmann R; Goldman JM; Cross NC
Bone Marrow Transplant; 1996 May; 17 Suppl 3():S41-4. PubMed ID: 8769700
[TBL] [Abstract][Full Text] [Related]
3. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
4. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
[TBL] [Abstract][Full Text] [Related]
5. Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction.
Hochhaus A; Lin F; Reiter A; Skladny H; Mason PJ; van Rhee F; Shepherd PC; Allan NC; Hehlmann R; Goldman JM; Cross NC
Blood; 1996 Feb; 87(4):1549-55. PubMed ID: 8608246
[TBL] [Abstract][Full Text] [Related]
6. Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies.
Talpaz M; Estrov Z; Kantarjian H; Ku S; Foteh A; Kurzrock R
J Clin Invest; 1994 Oct; 94(4):1383-9. PubMed ID: 7929813
[TBL] [Abstract][Full Text] [Related]
7. Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon.
Lion T; Gaiger A; Henn T; Hörth E; Haas OA; Geissler K; Gadner H
Leukemia; 1995 Aug; 9(8):1353-60. PubMed ID: 7643624
[TBL] [Abstract][Full Text] [Related]
8. Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients.
Guo JQ; Lin H; Kantarjian H; Talpaz M; Champlin R; Andreeff M; Glassman A; Arlinghaus RB
Leukemia; 2002 Dec; 16(12):2447-53. PubMed ID: 12454751
[TBL] [Abstract][Full Text] [Related]
9. Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-alpha-based therapy.
Martinelli G; Testoni N; Amabile M; Bonifazi F; De Vivo A; Farabegoli P; Terragna C; Montefusco V; Ottaviani E; Saglio G; Russo D; Baccarani M; Rosti G; Tura S
Bone Marrow Transplant; 2000 Apr; 25(7):729-36. PubMed ID: 10745258
[TBL] [Abstract][Full Text] [Related]
10. Detection of bcr-abl transcript in chronic myelogenous leukemia patients by reverse-transcription-polymerase chain reaction and capillary electrophoresis.
Martinelli G; Testoni N; Montefusco V; Amabile M; Saglio G; Ottaviani E; Terragna C; Bonifazzi F; de Vivo A; Pane F; Rosti G; Tura S
Haematologica; 1998 Jul; 83(7):593-601. PubMed ID: 9718863
[TBL] [Abstract][Full Text] [Related]
11. Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity.
Kurzrock R; Estrov Z; Kantarjian H; Talpaz M
J Clin Oncol; 1998 Apr; 16(4):1526-31. PubMed ID: 9552062
[TBL] [Abstract][Full Text] [Related]
12. Minimal residual disease in interferon-treated chronic myelogenous leukemia: results and pitfalls of analysis based on polymerase chain reaction.
Dhingra K; Kurzrock R; Kantarjian H; Baine R; Eastman PS; Ku S; Gutterman JU; Talpaz M
Leukemia; 1992 Aug; 6(8):754-60. PubMed ID: 1640725
[TBL] [Abstract][Full Text] [Related]
13. Real-time quantification of different types of bcr-abl transcript in chronic myeloid leukemia.
Amabile M; Giannini B; Testoni N; Montefusco V; Rosti G; Zardini C; Terragna C; Buonamici S; Ottaviani E; Soverini S; Fiacchini M; Bassi S; de Vivo A; Trabacchi E; Saglio G; Pane F; Baccarani M; Tura S; Martinelli G
Haematologica; 2001 Mar; 86(3):252-9. PubMed ID: 11255271
[TBL] [Abstract][Full Text] [Related]
14. [Detection of bcr-abl transcripts in "minimal residual disease" in chronic myelogenous leukemia by nested polymerase chain reaction (PCR)].
Cathomas G; McGandy C; Diamantis I; Tichelli A; Gudat F
Verh Dtsch Ges Pathol; 1994; 78():314-7. PubMed ID: 7534004
[TBL] [Abstract][Full Text] [Related]
15. Detection of bcr-abl mRNA in single progenitor colonies from patients with chronic myeloid leukemia by PCR: comparison with cytogenetics and PCR from uncultured cells.
Schulze E; Krahl R; Thalmeier K; Helbig W
Exp Hematol; 1995 Dec; 23(14):1649-54. PubMed ID: 8542960
[TBL] [Abstract][Full Text] [Related]
16. [Influence of IFN-alpha and IFN-alpha combined with GM-CSF on expression of the genes related to cell apoptosis of MNCs from bone marrow in CML patients].
Tang LJ; Chen HC; Peng XH
Hunan Yi Ke Da Xue Xue Bao; 2000 Dec; 25(6):570-2. PubMed ID: 12516408
[TBL] [Abstract][Full Text] [Related]
17. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C.
Müller MC; Gattermann N; Lahaye T; Deininger MW; Berndt A; Fruehauf S; Neubauer A; Fischer T; Hossfeld DK; Schneller F; Krause SW; Nerl C; Sayer HG; Ottmann OG; Waller C; Aulitzky W; le Coutre P; Freund M; Merx K; Paschka P; König H; Kreil S; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2003 Dec; 17(12):2392-400. PubMed ID: 14523462
[TBL] [Abstract][Full Text] [Related]
18. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia.
Kantarjian HM; Talpaz M; Cortes J; O'Brien S; Faderl S; Thomas D; Giles F; Rios MB; Shan J; Arlinghaus R
Clin Cancer Res; 2003 Jan; 9(1):160-6. PubMed ID: 12538464
[TBL] [Abstract][Full Text] [Related]
19. Persistence of BCR/ABL mRNA-expressing bone-marrow cells in patients with chronic myelogenous leukemia in complete cytogenetic remission induced by interferon-alpha therapy.
Eberlé F; Toiron Y; Camerlo J; Lafage M; Sainty D; Arnoulet C; Raineri V; Gabert J; Maraninchi D; Mannoni P
Leuk Lymphoma; 1995 Jun; 18(1-2):153-7. PubMed ID: 8580818
[TBL] [Abstract][Full Text] [Related]
20. Possible correlation between fusion pattern of BCR/ABL mRNA and clinical response to alpha-interferon in chronic myelogenous leukemia.
Inoue T; Tojo A; Tsuchimoto D; Okamoto S; Ogura H; Tani K; Ozawa K; Shibuya M; Asano S
Leukemia; 1992 Sep; 6(9):948-51. PubMed ID: 1518306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
